[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

Author Index: A

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
115 - A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS
160 - Impact of Azacitidine (AZA) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Myelodysplastic Syndromes (MDS): A Large-Scale Study on Behalf of the SFGM-TC and GFM Groups
609 - Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)
972 - Impact of the Provisional Revised-IPSS (R-IPSS) in 265 MDS Patients Treated with Azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience
1726 - Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA)
2564 - Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)
2786 - Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q
2790 - Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib 
4132 - Allogeneic Hematopoietic Peripheral Blood Stem-Cell Transplantation From HLA-Identical Siblings Versus Allelic-Matched Unrelated Donors (10/10 high resolution) in Patients with Acute Myeloid Leukemia and Myelodyplasic Syndrome After Reduced Intensity Conditioning 
120 - Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS)
457 - Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction
461 - Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS
607 - Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
767 - Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia
875 - Inotuzumab Ozogamycin (I0), a CD22 Monoclonal Antibody Conjugated to Calecheamicin, Is Active in Refractory-Relapse Acute Lymphocytic Leukemia (R-R ALL)
1496 - Outcomes in Obese and Overweight Acute Myeloid Leukemia (AML) Patients Receiving Chemotherapy Dosed According to Actual Body Weight
1720 - Validating the Lower-Risk MD Anderson Prognostic Scoring System (LR-PSS) and the Revised International Prognostic Scoring System (IPSS-R) for Patients with Myelodysplastic Syndromes
2015 - Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS)
2552 - Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia
2555 - Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study
2570 - Fluoroquinolone Prophylaxis in Acute Myeloid Leukemia (AML) Patients Undergoing Post-Remission Chemotherapy Reduces Hospital Admission Rates
2594 - Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy
2600 - A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML)
3595 - Cigarette Smoking Significantly Increases the Risk of Invasive Fungal Disease (IFD) in Acute Myeloid Leukemia (AML) Patients Undergoing Induction Chemotherapy
3830 - A Proof of Principle Clinical Trial in Myelodysplastic Syndromes of Non-Cytotoxic Differentiation Therapy with Decitabine
4137 - The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities
94 - Lymphoma in Pregnancy:  Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis
442 - The Bruton’s Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial
443 - Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma:  A Phase 2 Study Update
959 - Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma
1568 - Validation of the Elderly IPI (E-IPI) for Patients with Diffuse Large B Cell Lymphoma Using An Independent Data Set From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
1603 - Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496
2686 - Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience
2951 - Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom’s Macroglobulinemia
3068 - Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results
3091 - Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas
3701 - A Phase II Trial of Ofatumumab in Subjects with Waldenstrom’s Macroglobulinemia
3711 - Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
- Advanced Stage: Optimizing Initial Treatment
112 - Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies
453 - Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party
786 - Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509
1023 - An Observational Multicenter Study to Assess the Cost of Illness and Quality of Life in Patients with Myelodysplastic Syndromes in Italy
1682 - Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year
1686 - APPLICATION of EUTOS SCORE IN  CHRONIC Myeloid LEUKEMIA  AFFECTING VERY Elderly (>75 years) PATIENTS
2756 - Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial)
2770 - Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?
2799 - Treatment with Erythropoietic Stimulating Agents in IPSS Lower Risk MDS: Outcome Comparison Between 5q- and Non 5q- MDS Cases
3783 - Complete Cytogenetic Response After 3 Months Is a Very Early Indicator of Good Response to Imatinib As Front-Line Treatment in Chronic Myelogenous Leukemia
3854 - Risk Factors for Thrombosis Vary According to Age in Patients with Essential Thrombocythemia: a Retrospective Analysis of 1090 Patients from the “Gruppo Laziale SMPC Ph Negative “
569 - TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group
938 - FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML:  A Children’s Oncology Group Report
939 - Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry;  A Report From the Children’s Oncology Group AML Protocol AAML0531
1444 - The Prognostic Effect of High WT1 Gene Expression in Pediatric AML Depends on WT1 SNP rs16754 Status: A Report From the Children’s Oncology Group (COG)
2617 - Merging of Children’s Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children’s Oncology Group
3489 - Clinical Significance of CD33 Non-Synonymous Single Nucleotide Polymorphisms (SNPs) in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozogamicin-Containing Chemotherapy
3544 - Single Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Pediatric Patients with De Novo Acute Myeloid Leukemia (AML): Validation Study Results
3545 - Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children’s Oncology Group
3555 - The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group
320 - Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT)
662 - Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results
892 - Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS ; Results of a Randomized Phase III Study
894 - Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd
2005 - Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90  Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
2006 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival
3003 - Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)
3072 - Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation 
3083 - High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies
3106 - Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors
4118 - Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience
4138 - 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years
407 - Landmark Analyses of DNMT3A Mutations in Hematological Malignancies 
413 - Evaluation of the New Genetic Risk Classification of the European LeukemiaNet Recommendations in 1,110 Patients with De Novo AML and Proposal of a Refined Version
416 - ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome
418 - Prognostic Value of “Monosomal Karyotype” in Comparison to “Complex Aberrant Karyotype” in AML: A Study on 824 Cases with Aberrant Karyotype
747 - Monitoring of Minimal Residual Disease Using Next-Generation Deep-Sequencing in 460 Acute Myeloid Leukemia Cases identifies RUNX1 Mutated Patients with Resistant Disease
750 - Mathematical Modeling and Comparisons of Relapse Patterns in AML with 11q23/MLL translocations and Normal Karyotype AML with MLL-PTD
968 - Cytogenetic Clonal Evolution in MDS Is Associated with Shifts towards Unfavorable Karyotypes According to IPSS and Shorter Overall Survival: A Study on 988 MDS Patients Studied Sequentially by Chromosome Banding Analysis
1443 - Multilineage Dysplasia Has No Prognostic Impact in 108 Adult Patients with CEBPA Mutated AML Supporting the WHO Proposal to Classify These Patients As A Molecularely Defined Unique Entity
1722 - Multiparameter Flow Cytometry in Patients with Suspected Myelodysplastic Syndromes Adds Significant Prognostic Information: A Study on 1,013 Patients
2517 - Sensitive Monitoring of Minimal Residual Disease Status in CEBPA-Mutated Acute Myeloid Leukemia Using Amplicon Deep-Sequencing
2518 - Analysis of the IDH1G105 (SNPrs11554137) Polymorphism in 961 AML Patients and in a Large Cohort of 475 Healthy Controls
2531 - A NUP98-NSD1 Fusion Gene Can Be Detected in a Small Subset of Adult AML Patients with Normal Karyotype
2560 - Methylation of the Proximal, Distal and Core Promoter of CEBPA in 574 Cases with Normal Karyotype AML and 44 with t(8;21) Disclosed Different Frequencies but No Impact on Prognosis
2787 - Serial Assessment of Patients with Suspected Myelodysplastic Syndromes: Significance of Flow Cytometric Findings As Validated by Cytomorphology, Cytogenetics, and Molecular Genetics
2792 - Next-Generation Deep-Sequencing Enables a Quantitative Monitoring of RUNX1 Mutations in 534 Patients with Myelodysplastic/Myeloproliferative Neoplasms and Myelodysplastic Syndromes
3517 - Specific Molecular Mutations with Prognostic Relevance in AML with Normal Karyotype Are Also Associated with Outcome in AML with Aberrant Karyotype: A Study on 1981 Cases 
3583 - Patients with Therapy-Related Myeloid Disorders Share Genetic Features but Can Be Separated by Blast Counts and Cytogenetic Risk Groups Into Prognostically Relevant Subgroups
3796 - Prognosis of MDS Subtypes RARS, RCMD and RCMD-RS Does Not Differ by Cytomorphologic Criteria but Cytogenetics Allows to Delineate a Subgroup with Inferior Clinical Course
3805 - Flow Cytometric Assessment of Myeloid Nuclear Differentiation Antigen (MNDA) Expression in Myelodysplastic Syndromes As a Diagnostic Marker
257 - High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of High Dose AraC  
317 - Autologous Peripheral Blood Stem-Cell (PBSC) Collection Is Not  Impaired by Bortezomib-Thalidomide-Dexamethasone (VTD) Induction Therapy in Newly Diagnosed Multiple Myeloma (MM)
2596 - Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells
2610 - Clofarabine in Combination with a Standard Remission Induction Regimen (AraC and idarubicin) in Patients with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS):Phase I Results of An Ongoing Phase I/II Study of the EORTC-LG and GIMEMA(EORTC GIMEMA 06061 / AML-14A trial)
3612 - High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) During Induction and IL-2 Vs Observation After Consolidation/Autologous Stem Cell Transplantation in Patients with Acute Myelogenous Leukemia (AML): Final Report of the AML-12 Trial of EORTC and GIMEMA Leukemia Groups on the Value of Low Dose IL-2 Maintenance
3887 - Clinical Monoclonal B Cell Lymphocytosis Is a Strong Favorable Prognosticator Independent From Biological and Clinical Parameters
3906 - Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL)
1 - Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial
323 - Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd
891 - Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission.
1004 - Larger Numbers of Donor Naïve CD8+ T-Cells and Plasmacytoid Dendritic Cell Precursors In Allogeneic BM Grafts From Unrelated Donors Are Associated with Improved Survival: Results From BMT CTN 0201
1910 - Distinct Role of Antigen-Specific Tc1 and Tc17 Cells in Tumor Eradication In Vivo
3022 - Phase II Study of  a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression
4002 - Characterization of Clonotypic B Cell Progenitors in Bone Marrow of Multiple Myeloma Patients
4023 - Prevention of Graft-Versus-Host Disease by HY-Specific Induced Tregs Through Activation-Dependent Manner
4060 - Evaluation of a Risk-Based Algorithm for the Utilization of Plerixafor As Primary Mobilization of CD34+ Cells in Autologous Hematopoietic Cell Transplant Candidates
4158 - A Phase 2 Study of Bortezomib Plus High-Dose Melphalan (Mel/Vel) Conditioning for Autologous Hematopoietic Cell Transplantation In Multiple Myeloma
1 - Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial
662 - Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results
894 - Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd
1944 - Phase I/II Trial of Fludarabine in Combination with Intravenous Busulfan and Allogeneic Progenitor Cell Support for Patients with High Risk Hematologic Malignancies; Dose Matters in Reduced Intensity Regimens
2005 - Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90  Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
2006 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival
2039 - Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era
3003 - Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL)
3009 - Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels
3083 - High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies
4047 - Prediction of Apheresis Peripheral Blood Stem Cell Yield Based on Pre Apheresis Absolute Peripheral Blood Stem Cell Counts
4058 - Predictors of Stem Cell Yield Via Apheresis in Patients Undergoing Stem Cell Mobilization
4118 - Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience
4138 - 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years
128 - Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma
133 - Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma
136 - Investigational Agent MLN9708 Target Tumor Suppressor MicroRNA-33b in Multiple Myeloma Cells
297 - Whole Genome Sequencing Defines the Clonal Architecture and Genomic Evolution in Myeloma: Tumor Heterogeneity with Continued Acquisition of New Mutational Change
302 - Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM)
305 - BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma
476 - Continued Overall Survival Benefit After 5 Years’ Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial
480 - Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial
634 - Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results
811 - Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial
815 - Perifosine Plus Bortezomib and Dexamethasone in Relapsed / Refractory Multiple Myeloma Patients Previously Treated with Bortezomib:  Final Results of a Phase I/II Trial
883 - Targeting Brouton’s Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment
1024 - The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development
1377 - Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes
1419 - Mir-222-221 Induce Dexamethasone Resistance by Targeting BBC3/PUMA in Human Multiple Myeloma
1442 - Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index
1810 - Alternate Splicing Factor Fox2 Affects Growth and Survival of Multiple Myeloma Cells
1816 - Gene Mutations Detected by Whole-Exome Sequencing and Recurrent Cytogenetic Abnormalities Are Independent Events in Multiple Myeloma
1820 - Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance
1838 - Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing
1841 - A Novel Acanthoic Acid Analog NPI-1342 Blocks IκB Kinase-α and Trigger In Vitro and In Vivo cytotoxicity in Multiple Myeloma Cells
1874 - Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
2705 - Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom’s Macroglobulinemia
2706 - Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia
2902 - Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)
2910 - MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence
2913 - Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma
2916 - DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma
2920 - Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells
2951 - Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom’s Macroglobulinemia
3966 - Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide
- New Insights Into Therapeutic Targets in Myeloma
320 - Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT)
892 - Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS ; Results of a Randomized Phase III Study
2005 - Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90  Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
2006 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival
2013 - Ex-Vivo T Cell-Depleted Versus Unmodified Allografts in Patients with Acute Myeloid Leukemia in First Complete Remission: A Comparison of Outcomes in Two Institutions
2037 - Chromosome 7 Abnormalities in Allogeneic Transplantation for AML and MDS
3072 - Pre-Transplant Minimal Residual Disease Detected by Multiparameter Flow Cytometric Analysis Predicts for Disease Relapse in Adult Patients with Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Stem Cell transplantation 
3083 - High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies
4118 - Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience
66 - Antagonizing IAPs by SMAC Mimetic TL32711 Induces Apoptosis in AML Cells Including AML Stem/Progenitor Cells Alone and in Combination with Chemotherapy
238 - Survivin Is Highly Expressed in AML Stem Cells and Predicts Poor Clinical Outcome
396 - The PP2A Subunit B55α Suppresses Survival Signaling in Acute Myeloid Leukemia Cells
699 - Neo-Vasculogenesis In Vivo Is Facilitated by Oxygen Sensing Mesenchymal Stem and Pogenitor Cells
892 - Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS ; Results of a Randomized Phase III Study
926 - TGF-β Neutralizing Antibody 1D11 Inhibits LIF-JAK-Stat3 Signaling and Enhances Cytarabine Induced Apoptosis in AML Cells in Bone Marrow Microenvironment
1323 - Human Extramedullary Bone and Bone Marrow in Mice: First In Vivo Model of a Genetically Controlled Hematopoietic Environment
1424 - Growth-Inhibitory Effects of a Class I PI3K Inhibitor GDC-0941 Are Modulated by Hypoxia-Induced mTOR Pathway Activation in Mantle Cell Lymphoma
1493 - FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations
1501 - Bone Marrow-Derived Adipocytes Promote Differentiation, Proliferation and Survival of Acute Monoblastic Leukemia Cells
1524 - Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen
1545 - Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
1547 - MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML
1550 - Clofarabine, Idarubicin, and Cytarabine (CIA) As Frontline Therapy for Patients Younger Than 61 Years with Newly Diagnosed Acute Myeloid Leukemia (AML)
2391 - Connective Tissue Growth Factor (CTGF) Regulates Mesenchymal Stromal Cell De-Differentiation Into Adipocyte Progenitors and Facilitates Leukemic Cell Homing to Extra-Medullary Bone Marrow
2448 - Arf and Ink4a Are Critical Factors Determining the Cell of Origin and Therapeutic Sensitivity in Myc-Induced Mouse Lymphoid Tumor
2480 - The Anti-Proliferative Effects of Hsp90 Inhibitor Tricyclic Coumarin GUT-70 and Geldanamycin Analog 17-DMAG in AML Cells in Hypoxia
2513 - High Expression of Autophagy Related Proteins Negatively Impacts Clinical Outcomes in Acute Myelogenous Leukemia--Time to Target Autophagy to Improve Therapy Outcomes?
2593 - Role of Connective Tissue Growth Factor (CTGF)  in Survival and Chemosensitivity of Acute Lymphoblastic Leukemia.    
3505 - Acquired Point Mutations of TKD Are Responsible for Sorafenib Resistance in FLT3-ITD Mutant AML
3623 - FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations
85 - The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma
88 - ALK-Negative Anaplastic Large Cell Lymphomas with 6p25.3 Translocations Show a Histone-Modifying Gene Expression Signature
429 - Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients
770 - IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom’s Macroglobulinemia
955 - Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma
1570 - Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression 
1572 - Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience
1586 - TGF-β Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL)
1640 - Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy
1926 - Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients
2642 - A Lymphoma-Associated Mutation in BAFF-R Drives Constitutive PI3K Signaling and Increased Expression of Pro-Survival Genes
2682 - Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies
3095 - A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM)
3642 - Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
3652 - Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma
3691 - UCH-L1 Is a Novel Regulator of mTOR Signaling That May Predict a Poor Response to mTOR Inhibition in Patients with B-Cell Lymphoma
307 - Donor B-Cell Alloantibody Deposition and Germinal Center Formation Are Required for the Development of Murine Chronic Gvhd and Bronchiolitis Obliterans
327 - A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation
494 - Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
649 - HHV-6-Associated Post-Transplantation Acute Limbic Encephalitis Following Cord Blood Stem Cell Transplantation: A Cohort Analysis
653 - FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation
3009 - Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels
3029 - Does Iron Overload Really Matter in Stem Cell Transplantation?
3031 - Pre-Emptive Rituximab for the Prevention of EBV-Related PTLD in Umbilical Cord Blood Transplantion Patients
3036 - Patterns of B Cell Activating Factor (BAFF) Levels, B Cell Recovery, and BAFF/B Cell Ratios Correlate with the Development of Chronic Graft-Versus-Host Disease (cGVHD) Following Hematopoietic Stem Cell Transplantation (HSCT)
3671 - Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation
4075 - Immune Reconstitution After Cord Blood Transplantation in Adults Depends on Activity of Thymic Epithelial Cells and Vascular Endothelial Elements
4150 - KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation
83 - Late Relapses Following All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Are Uncommon, Respond Well to Salvage Therapy and Occur Independently of Prognostic Factors At Diagnosis:  Long-Term Follow-up of North American Intergroup Study I0129
145 - Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes
156 - Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT) 
258 - Adding Mercaptopurine and Methotrexate to Alternate Week ATRA Maintenance Therapy Does Not Improve the Outcome for Adults with Acute Promyelocytic Leukemia (APL) in First Remission:  Results From North American Leukemia Intergroup Trial C9710
289 - Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies 
319 - Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes
326 - Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT)
579 - Novel Dual E-Selectin-CXCR4 Inhibitors Mobilize Human Acute Myeloid Leukemia (AML) Cells in the NODscid IL2Rγc-/- Xenograft and Confer Susceptibility to Cytarabine
663 - A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma
665 - Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes
666 - Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)
1432 - The CXCR4 Inhibitor Plerixafor Effectively Mobilizes Primary AML in NODscid IL2Rγc-/- Xenografts and Markedly Reduces but Does Not Eradicate Leukemia in Combination with Cytarabine +/- Clofarabine Chemotherapy
1446 - Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data
1464 - Identification of Differential Methylation Markers Among Cytogenetic Risk Groups of Acute Myeloid Leukemia
1497 - Survival After Failure of Initial Therapy for Newly-Diagnosed or Relapsed/Refractory AML At An Academic Center: Subsequent Clinical Trial Vs. Not
1498 - Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery
2510 - KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report
2520 - Prognostic Significance of FLT3 and NPM1 Mutations in Adults of Age 18-60 with De Novo Acute Myeloid Leukemia (AML) on SWOG S0106 Study: A Study by FHCRC and SWOG
2555 - Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study
2594 - Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy
3516 - Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG
3519 - DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report
3617 - Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm
3640 - Infusion of “off-the-shelf” Third Party Ex Vivo Expanded Cord Blood Progenitor Cells As Supportive Care Following Clofarabine with High Dose Cytarabine and Granulocyte Colony-Stimulating Factor Priming for the Treatment of AML
109 - Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation
605 - The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping’ Studies
785 - The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy
1680 - Assessment of BCR-ABL1 Transcript Levels At 3 Months Is the Only Requirement for Predicting Outcome for Patients with Chronic Myeloid Leukemia Treated with Imatinib
1932 - Plerixafor for Autologous Peripheral Blood Stem Cell Mobilization in Patients Previously Treated with Fludarabine or Lenalidomide
1945 - Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation
2993 - Stem Cell Mobilization in Poor Mobilizers Using Plerixafor and G-CSF with or without Chemotherapy: A European Perspective
3292 - Thrombopoietic Agonists Show Efficacy in ITP Related to Allogeneic Stem Cell Transplantation
3753 - Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets
3777 - Prolonged Survival Following Imatinib Failure for CML Patients in CP May Require Multiple TKI Strategies for Responding Patients
4052 - Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations
4103 - The Majority of Patients Receiving Donor Lymphocyte Infusions for Relapsed Chronic Myeloid Leukemia Remain PCR Positive Despite Maintaining Long-Term Remission
4125 - Allogeneic Stem Cell Transplantation Induces Long Term Survival in Pateitns with Advanced Chronic Myeloid Leukaemia:A Study of the British Society for Blood and Marrow Transplantation
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z